Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take,…
An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma…
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of…
In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths,…
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well…
The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park…
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
See our Cookie Privacy Policy Here
